2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Neoplasms
9
Breast Neoplasms
8
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
7
Endometrial Neoplasms
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
rucaparib
×
Clear all
NCT03654833
2023-03-14
MiST
University of Leicester
Phase 2
Unknown
186 enrolled